Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EXTERNAL BEAM RADIATION

Phase 2Biologic

RRutgers, The State University of New Jersey

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone MetastasesRecruiting

Bone MetastasesPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Bone Metastases

NCT05419518

Clinical

Trials by Indication[1]

Bone Metastases1 trial

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05419518·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EXTERNAL BEAM RADIATION. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EXTERNAL BEAM RADIATION compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EXTERNAL BEAM RADIATION. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rutgers, The State University of New Jersey company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: RRutgers, The State University of New Jersey

Related News